Genentech's Lucentis dubbed 'breakthrough' in diabetic retinopathy
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation to Lucentis (ranibizumab injection), a vascular endothelial growth factor inhibitor, as a treatment of diabetic retinopathy.